Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONT01 in Lupus Nephritis and SLE
NCT07107659Phase 1Recruiting
- Sponsor
- Hospital for Special Surgery
- Start
- Sep 2026
- Primary completion
- May 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ontegimod in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Hospital for Special Surgery. Primary endpoint: Adverse Events, Study Completion versus Withdrawal at 18 weeks. Started Sep 2026; status: recruiting.
02
Drugs
ontegimod
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07107659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07107659.